98%
921
2 minutes
20
Pertussis, a respiratory disease caused by , remains a global health challenge despite decades of vaccination. The inclusion of diphtheria, tetanus, and whole-cell pertussis (DTwP) vaccines in the World Health Organization (WHO) Expanded Program on Immunization (EPI) in 1974 significantly reduced incidence worldwide. However, since the 1980s, pertussis resurgence has been observed in both high-income and low- and middle-income nations. The COVID-19 pandemic further disrupted vaccination, exacerbating outbreaks. Contributing factors include genetic mutations in , vaccine differences, waning immunity, inadequate immunization, disease cyclicity, and the impact of the COVID-19 pandemic, coupled with improved surveillance, diagnostics, and awareness. Pertussis continues to impose a substantial disease burden, with infants being the most vulnerable. This review examines pertussis epidemiology from 1980 to 2023, analyzing resurgence drivers and evaluating current progress and persistent challenges in vaccination strategies and surveillance efforts.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12153400 | PMC |
http://dx.doi.org/10.1080/21645515.2025.2513729 | DOI Listing |
Pulm Ther
September 2025
Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Straße 173, 55216, Ingelheim am Rhein, Germany.
Introduction: The modification of an inhaler's air flow resistance influences a patient's inhalation flow profile, thereby affecting the exit velocity of an aerosol leaving the Respimat® mouthpiece. A slower inhalation maneuver results in reduced plume velocity and thus a decreased oropharyngeal deposition due to reduced impaction. This could not only lead to fewer unwanted side effects associated with inhaled therapies, but also enhance lung deposition.
View Article and Find Full Text PDFPatient
September 2025
Patient Services, Anthony Nolan, 2 Heathgate Place, London, NW3 2NU, UK.
Background: There is increasing interest in using patient-reported outcome measures (PROMs) to assess quality of life (QoL) following hematopoietic cell transplant (HCT). However, there is limited consensus on how such data should be collected within HCT services. This survey study investigated health professionals (HCPs) views towards QoL data collection and factors affecting the use of PROMs within HCT centres in the UK.
View Article and Find Full Text PDFJ Gen Intern Med
September 2025
UCSF Benioff Homelessness and Housing Initiative, University of California, San Francisco, CA, USA.
Background: Older homeless-experienced adults are at higher risk of loneliness than general older adults. Loneliness is associated with multiple adverse health and mental health outcomes. Less is known about factors contributing to loneliness among older adults who experience homelessness.
View Article and Find Full Text PDFVirchows Arch
September 2025
Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais, Minas Gerais, Av. Antônio Carlos, Pampulha, Belo Horizonte, 31270-901, Brazil.
Plasmablastic lymphoma (PBL) is a rare and aggressive non-Hodgkin lymphoma with a poor prognosis and short survival rates. It is classified as a large B-cell lymphoma subtype, but carries a plasmacytic immunophenotype. Therefore, PBL has pathogenetic overlaps with diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) and plasma cell neoplasms (PCNs).
View Article and Find Full Text PDFNat Aging
September 2025
Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.
Clinical Alzheimer's disease is currently characterized by cerebral β-amyloidosis associated with cognitive impairment. However, most cases of Alzheimer's disease are associated with multiple neuropathologies at autopsy. The peripheral protein changes associated with these disease endophenotypes are poorly understood.
View Article and Find Full Text PDF